Abstract
Hepatitis B virus (HBV) infection constitutes one of the major global public health problems. Not only India and Nepal, East Asia is fighting with the same. About 30 percent of the world's population has serological evidence of current or past infection with HBV. By virtue of its different stage of presentation in different age groups of patients and the rapid mutation in the virus, the treatment of HBV requires thorough work-up and regular monitoring. Many new concepts have evolved in last decade in managing these patients, such as HBV Genotype, HBV DNA quantification and mutation analysis. The introduction of oral antivirals in the treatment of HBV infection has revolutionized the treatment.
MeSH terms
-
Adenine / analogs & derivatives
-
Adenine / therapeutic use
-
Antiviral Agents / therapeutic use
-
DNA, Viral / analysis
-
Female
-
Guanine / analogs & derivatives
-
Guanine / therapeutic use
-
Hepatitis B Surface Antigens / analysis
-
Hepatitis B, Chronic / drug therapy
-
Hepatitis B, Chronic / epidemiology
-
Hepatitis B, Chronic / physiopathology
-
Hepatitis B, Chronic / therapy*
-
Humans
-
Organophosphonates / therapeutic use
-
Pregnancy
-
Pregnancy Complications, Infectious / drug therapy
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Tenofovir
-
Treatment Outcome
Substances
-
Antiviral Agents
-
DNA, Viral
-
Hepatitis B Surface Antigens
-
Organophosphonates
-
Reverse Transcriptase Inhibitors
-
entecavir
-
Guanine
-
Tenofovir
-
Adenine